Cramer said that Alkermes is simply not getting enough credit for Vivitrol, but the company is also not a one-trick pony. He said the company has partnerships with companies including Bristol Meyers-Squibb ( BMY) for some of its other drugs and has other a sizable drug pipeline. Trading at just 17 times earnings with a 25% drug rate, Cramer called shares of Alkermes "insanely cheap."
Here's what Cramer had to say about callers' stocks during the "Lightning Round": Edwards Lifesciences ( EW): "This is the solution for people who don't want open heart surgery. I'm sticking with this one." MarkWest Energy Partners ( MWE): "Everyone has given up on this one but here they come. Enterprise Products Partners ( EPD) at a 52-week high." VirnetX ( VHC): "I am not against it, I'm for it." Exelixis ( EXEL): "This is one of my favorite biotech spec plays. " Alaska Air Group ( ALK): "I used to like that one but now I'm going with US Airways Group ( LCC)." Kinross Gold ( KGC): "I'm not liking the gold stocks, especially that one. I like the SPDR Gold Shares ( GLD)." Skyworks Solutions ( SWKS): "I would ring the register. The tech group is not so great here. " Polycom ( PLCM): "Listen, the videoconferencing business is horrible. I'd get out." Facebook: "I'm hearing the mobile ad scene is bad. I worry about it and I'm scared of it." ConocoPhillips ( COP): "I think we should pull the trigger. I like the upside."
Off the Charts
In the "Off The Charts" segment, Cramer went head to head with colleague Ed Ponsi over the charts of restaurant stocks to see which ones are rising to the top of the heap. According to Ponsi, those stocks include McDonald's ( MCD), Dunkin Brands ( DNKN) and Domino's Pizza ( DPZ). Ponsi said that McDonald's has been out of favor for months, but this latest pullback is a buyable one. The charts are displaying an inverted head-and-shoulder formation, a powerfully bottoming indicator, and with shares now trading above the neckline, Ponsi felt shares could see a 6% gain from current levels. Dunkin Brands was also displaying a powerful pattern, only this time it was the stock's 50-day moving average. Ponsi noted that since its initial public offering last year, Dunkin's 50-day moving average has been a floor of support for the stock, making it a buy, buy, buy.